Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery
Completed · Phase 2
Conditions studied: Melanoma (Skin)
In brief
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known what preparation of vaccine therapy is most effective for treating melanoma. PURPOSE: Randomized phase II trial to study the effectiveness of tyrosinase/gp100 peptide vaccine in treating patients who have stage II melanoma that can be removed by surgery.
Key facts
- Study ID
- NCT00003274
- Run by
- University of Southern California
- People needed
- 48
- Starts
- 1998-03-01
- Expected to finish
- 2002-11-01
- Last updated by the study team
- 2014-05-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.